The Limited Times

Now you can see non-English news...

AstraZeneca vaccine: Oxford University suspends trials on children

2021-04-06T21:28:30.123Z


No more question, until a new opinion from the British regulator, of injecting doses of vaccine against Covid-19 to children aged 6 to


Oxford University was testing its vaccine on 300 volunteers aged 6 to 17, according to RFI.

Tuesday, pending the opinion of the British regulator, she announced that she was suspending tests on children of this serum against Covid-19 that she developed with the Anglo-Swedish laboratory AstraZeneca.

"If there are no concerns regarding the safety of the pediatric clinical trial, we await further information from the MHRA" (Medicines and Healthcare products Regulatory Agency, the British regulator) "on the rare cases of thrombosis which have been reported in adults, before proceeding with new vaccinations in the trial, ”said the British university.

READ ALSO>

AstraZeneca vaccine: three new cases of thrombosis detected in France, including two deaths

Monitoring has been put in place.

"Parents and children should continue to attend scheduled visits and can contact the sites where the trial is being held if they have any questions," the university statement added.

Seven fatal cases in the United Kingdom

The MHRA is investigating reports of blood clots in patients who have received the AstraZeneca vaccine.

Seven fatal cases have been identified in the United Kingdom out of a total of 30 identified cases, the regulator said on Saturday, while more than 18 million doses of the AstraZeneca vaccine were administered in the country.

MHRA official June Raine has since asserted that people should "continue to be vaccinated when instructed to do so."

"Our in-depth and detailed examination is underway regarding reports of very rare and specific types of blood clots with low platelet counts following AstraZeneca's Covid-19 vaccine," she continued, adding that "no decision has not yet been taken on possible regulatory action ”.

The European agency in expectation

A World Health Organization (WHO) official Rogerio Pinto de Sa Gaspar said on Tuesday that the risk / benefit balance continued to weigh "largely" in favor of the use of AstraZeneca's anti-Covid vaccine.

Earlier today, an official from the European Medicines Agency (EMA) mentioned the existence of a "link" between the AstraZeneca vaccine and the cases of thrombosis observed after its administration, in an interview with the Italian daily Il Messaggero published Tuesday.

The European agency immediately clarified that its security committee "has not yet reached a conclusion and (that) the examination is currently underway".

For several weeks, suspicions have appeared on possible serious side effects, but rare, after the observation in people vaccinated with AstraZeneca of cases of atypical thrombosis.

Vaccine suspended in Norway and Denmark

As a precaution, several countries have decided to no longer administer this vaccine below a certain age, 55 years for France, 60 years in general for Germany and the Netherlands.

Norway and Denmark have even suspended its use for now.

For its part, AstraZeneca assured in March that there was "no evidence of aggravated risk", and assured Saturday that "patient safety" was its "main priority".

Coronavirus Newsletter

Update on the Covid-19 epidemic

Subscribe to the newsletterAll newsletters

The Anglo-Swedish laboratory AstraZeneca was not the only one interested in children and adolescents.

According to RFI, other similar research has been launched, in particular by Pfizer in the United States, but so far they have been limited to more than 12 years.

Once this trial is completed, the health authorities will still have to validate the marketing of the vaccine for young people.

Source: leparis

All life articles on 2021-04-06

You may like

Trends 24h

Latest

© Communities 2019 - Privacy

The information on this site is from external sources that are not under our control.
The inclusion of any links does not necessarily imply a recommendation or endorse the views expressed within them.